NDA 204063 · Biogen
Tecfidera
Dimethyl Fumarate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Mar 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Mar 27, 2013
Approved uses
4
Original approval plus efficacy supplements
Registered trials
236
49 Phase 3, 19 recruiting
FAERS reports
122,568
40,867 serious, 2,171 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 4, 2025.
TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Mechanism: The mechanism by which dimethyl fumarate (DMF) exerts its therapeutic effect in multiple sclerosis is unknown. DMF and the metabolite, monomethyl fumarate (MMF), have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 10, 2023 Supplement 29 · Efficacy LetterLabel
- Feb 5, 2020 Supplement 23 · Efficacy LetterLabel
- Dec 3, 2014 Supplement 3 · Efficacy LabelLetter
- Mar 27, 2013 Original approval · Type 1 - New Molecular Entity NovelLabelOther Important Information from FDALetter
2 products under this application
- TECFIDERA · DIMETHYL FUMARATE 120MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB
- TECFIDERA · DIMETHYL FUMARATE 240MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dimethyl" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05675410 · 1,875 participants (planned) · Start May 11, 2023 · Primary completion Apr 28, 2031
Drug: Bleomycin Sulfate; Brentuximab Vedotin and 11 more · For: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 419 sites in all
- BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00835770 · 1,736 participants · Start Feb 3, 2009 · Primary completion Nov 8, 2019
Drug: dimethyl fumarate; Placebo · For: Relapsing-Remitting Multiple Sclerosis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mesa, Arizona · 246 sites in all
- Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic SyndromePivotal-lookingCompleted
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
NCT02960711 · 1,600 participants · Start Feb 2014 · Primary completion Jul 2019
Drug: Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]; Ludipress, mg stereate, micronized hydrated silica, talcum · For: Metabolic Syndrome
Sites: Milan, Italy
- Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00451451 · 1,417 participants · Start Jun 2007 · Primary completion Aug 2011
Drug: BG00012; Placebo and 1 more · For: Relapsing-Remitting Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Huntsville, Alabama · 195 sites in all
- Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT00420212 · 1,234 participants · Start Jan 2007 · Primary completion Feb 2011
Drug: BG00012; Placebo · For: Relapsing-Remitting Multiple Sclerosis
Sites: Gilbert, Arizona; Phoenix, Arizona; San Francisco, California · 159 sites in all
BiogenBiogen (BIIB)
NCT01930708 · 1,114 participants · Start Oct 31, 2013 · Primary completion Mar 31, 2016
Drug: dimethyl fumarate · For: Relapsing-Remitting Multiple Sclerosis; Multiple Sclerosis
Sites: Innsbruck, Austria; Klagenfurt, Austria; Linz, Austria · 90 sites in all
- A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02634307 · 1,057 participants · Start Dec 10, 2015 · Primary completion Jun 1, 2021
Drug: ALKS 8700 · For: Multiple Sclerosis
Sites: Cullman, Alabama; Phoenix, Arizona; Tucson, Arizona · 115 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- flushing17,125
- nausea8,981
- diarrhoea8,302
- multiple sclerosis relapse8,147
- fatigue6,970
- multiple sclerosis5,766
- vomiting5,659
- memory impairment5,573
- gastric disorder5,551
- abdominal pain upper5,420
- drug ineffective5,238
- pruritus5,080
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 14 |
| 2013 | 14,596 |
| 2014 | 18,283 |
| 2015 | 12,884 |
| 2016 | 13,524 |
| 2017 | 12,338 |
| 2018 | 12,142 |
| 2019 | 10,538 |
| 2020 | 9,477 |
| 2021 | 6,132 |
| 2022 | 5,229 |
| 2023 | 3,259 |
| 2024 | 1,755 |
| 2025 | 1,526 |
| 2026 | 863 |
Recalls
1 FDA enforcement reports for this application.
Jun 23, 2020 · Class III · Terminated
cGMP deviations: one lot of the product was distributed to US Markets despite being rejected during in-process control.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tecfidera (Dimethyl Fumarate)
2024 spending
$163M
Beneficiaries
2,117
16,641 claims
Per beneficiary
$76,921
$149.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,054,984,601 |
| 2021 | $569,199,653 |
| 2022 | $343,225,607 |
| 2023 | $234,518,996 |
| 2024 | $162,842,335 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL, Graham NT, Catalano PJ, et al. · J Clin Oncol 2023 · Clinical Trial, Phase II, Multicenter Study
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Rindi LV, Zaçe D, Braccialarghe N, et al. · Drug Saf 2024 · Systematic Review, Meta-Analysis
- Pralidoxime in acute organophosphorus insecticide poisoning--a randomised controlled trial.
Eddleston M, Eyer P, Worek F, et al. · PLoS Med 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.
Okuda DT, Kantarci O, Lebrun-Frénay C, et al. · Ann Neurol 2023 · Randomized Controlled Trial, Multicenter Study
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Biogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.